Tengion, Inc. (TNGNQ)

Market Cap	40.00
Revenue (ttm)	n/a
Net Income (ttm)	-64.43M
Shares Out	40.21M
EPS (ttm)	-3.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,570
Average Volume	95
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	41.59
RSI	2.98
Earnings Date	n/a

About Tengion

Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 26
• Stock Exchange: OTCMKTS
• Ticker Symbol: TNGNQ